Protocol of Comparative Evaluation of Efficacy of Kulattha Gutika with Atorvastatin in the Management of Dyslipidemia (Medoroga)

Praveen Nandal a* and Sadhana Misar Wajpeyi a*

a Department of Kayachikitsa, Mahatma Gandhi Ayurveda College, Hospital & Research Centre, Salod (H), Datta Meghe Institute of Medical Science, (Deemed to be University), Sawangi (M), Wardha, India.

Authors’ contributions

This work was carried out in collaboration between both authors. Both authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i63B35251

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/80868

Received 20 October 2021
Accepted 27 December 2021
Published 29 December 2021

ABSTRACT

Introduction: The term ‘Dyslipidemia’ can be referred to Medoroga included under santarpananjayavadyadhi as per Ayurveda. In Dyslipidemia there is involvement of Tridosha with kaphadominance. Intake of unhealthy food, alcohol, cigarette smoking, stress and lack of physical activity are the main etiological factors of Dyslipidemia. According to Ayurveda Guru, Madhur, Sheet, Snigdha, Kapha Meda Vardhaka Ahar, Avyayam, Diwaswapa, Achinta and Bijadosha are the main causative factors for medoroga.

Aim and Objectives: Comparative evaluation of Efficacy of Kulattha Gutika and Atorvastatin in the management of Dyslipidemia (Medoroga).

Material and Methods: Study contains 60 patients of Dyslipidemia which will be divided into two equal groups (each contains 30 patients). Group A (Interventional) patients will be treated with KulatthaGutika1 gm thrice a day after meal with warm water for 45 days and Group B (Experimental group) will be given Tab, Atorvastatin 10 mg at bedtime with warm water for 45 days. Objective parameters like BMI, Lipid profile and Fasting Blood Sugar will be assessed before and after treatment. Incidence of Dyslipidemia as per prakriti will be assessed by analysing prakriti of each patient.

PG Scholar;
Professor;
*Corresponding author: E-mail: praveennandal320@gmail.com;
Discussion: Kulattha is indicated for medoroga in Bhavprakash due to its kaphamedohar property which may help in improving objective parameters.

Result: Subjective and Objectives outcomes will be statistically analysed by appropriate method.

Conclusion: Conclusion will be drawn from result obtained.

Keywords: Dyslipidemia; Medoroga; Kulattha Gutika; Atorvastatin; Santarpanjanya vyadhi.

1. INTRODUCTION

In terms of food, living standards, and the environment, human life is rapidly changing. A majority of the population suffers from metabolic diseases as a result of changes in eating habits and a sedentary lifestyle. Metabolic diseases are caused by changes in normal metabolic processes caused by aberrant chemical interactions in the body. Dyslipidemia is defined as a group of metabolic diseases involving lipoprotein metabolism, evidenced by an increase total cholesterol, triglycerides (TGs), or both, or a reduction in high density lipoprotein levels, or all three, can all lead to atherosclerosis at any age [1,2]. According to the ICMR-INDIAB study, hypercholesterolemia was prevalent in 13.9 percent of the population, hypertriglyceridemia was prevalent in 29.5 percent, low HDL-C was prevalent in 72.3 percent, and high LDL-C levels were prevalent in 11.8 percent. Ayurvedic texts do not provide any descriptions of dyslipidemia. As a result, it cannot be compared to a specific condition in Ayurveda. It falls under the category of Santarpanjanya Vyadhi. Due to similarities in their etiopathogenesis and clinical features, Shonitabhishtyangana, RasagataSnehaVriddhi (raised plasma lipid levels), RasaRaktagata Sneha Vriddhi (raised plasma and blood lipid levels), Medovriddhi (elevation of generalised fat), Medoroga (obesity), and AamiMedodhatu (abnormal The main etiological causes of Dyslipidemia are poor eating habits, a sedentary lifestyle, the existence of Dyslipidemia in the family, alcohol consumption, cigarette smoking, and stress [3,4]. According to Ayurveda the main causes of Medoroga are Guru, Madhuhr, Sheet, Snigdha, KaphaMeda Vardhaka Ahar, Avyayam, Diwaswapa, Achinta, and Bijadosha [5]. All of these Hetus aggravate the kapha and Meda, resulting in Strotorodha. The regular movement of Vayu is obstructed due to Strotorodha. This obstructed Vayu enters the Koshtha, causing Jatharagni sandhukshana (increased digestive capacity), which causes early digestion of ingested food, resulting in insatiable appetite and a desire for huge amounts of food. Agnimandya and Ama production, according to Dalhan, are to blame for the situation. The effective functioning of Agni is essential for all metabolic activity in the organism [6]. Food digestion is hampered by Agnimandya, which creates Ama. Ama is thought to be a crucial element in the aetiology of metabolic problems in Ayurveda. This ama obstructs the Strotas (metabolic process channels), resulting in disease development. Excess fat accumulates in the blood and adipose tissue due to a malfunction in fat metabolism. The creation of aberrant Poshaka Medodathu in huge quantities is caused by Medodhatwagnimandya. This improperly produced Poshaka Medodathu accumulates in vast quantities in Rasadhatu. The accumulation of Poshaka Medodathu leads to the development of a condition known as Dhemanipratichaya. Dhemanipratichaya is one of KaphaDosha's 20 NanatmajaVyadhis [7]. MedorogaSamprapti begins with inflamed Kapha and Medas accumulating in the various Strotas, resulting in Strotorodha. Shonitabhishtyangana is a condition in which there is an excessive concentration of Kapha and Medas in the Rasadhatu (plasma) and Raktadhatu (blood, and blood vessels) [8,9]. It adheres to the Upalepa and forms it within the dhmani's walls [10]. Acharya Charak prescribes karshana and kaphamedanashanachikitsa in Ayurveda to eradicate the KaphaMedaApatarpanaupalepa. Kulattha is mentioned in Bhavprakash [11] for the management of Medoroga which helps in Sampraptivighatana. Kulattha possesses Laghu, Ruksha and Tikshnaguna, KashayaRasa and due to its Ushna potency, it exhibits Vata-Kaphanashak Karma and Lekhan Karma, it also exhibits Medohar quality [12]. As, Atoravastin is a standard drug used in the treatment of dyslipidemia. So, in this study, Atoravastatin is used in control group.

2. RESEARCH GAPS ANALYSIS

Animal studies conducted on Kulattha showed its antihyperlipidemic, nephrolithic and antioxidant activity. Also, Kulattha is mentioned to exhibit medohar quality by its Lekhankarma. Thereare
large numbers of research studies available on Dyslipidemia. Shodhanachikitsa like Vamana, Virechana and Basti (Lekhana Basti) showed good results in improving lipid levels [13,14]. But all patients are not willing for procedures of Shodhanachikitsa. It is expensive, patients have to visit frequently to hospital, and have to follow pre and post operative procedures. Shodhanachikitsa cannot be used in patients having contraindicated for it. In such patients Shamanachikitsa can be given. In Shamanachikitsa most of the formulations have guggul as main ingredient. In Bhavaprakash Samhita it is mentioned to avoid long term consumption of guggul. The long term consumption of which have adverse effects like abdominal discomfort [15], impotency [16]. The Lekhana drugs available for dyslipidemia can also cause abdominal irritation in some patients. The patients having intolerance to Guggul and Lekhana drugs cannot consume it for a longer duration. Kulattha is described in Dhanyavarga so it can be safely used for long duration. It is cost effective and easily available. So present study is planned to evaluate efficacy of Kulattha in the management of Dyslipidemia in human beings.

Trial plan: The study design is Double arm Randomized Standard controlled single blind clinical trial. It is an interventional study having 1:1 ratio on both parallel groups.

Research Question: Whether Kulattha Gutika is as effective as Atorvastatin in the management of Dyslipidemia?

Hypothesis:

Null hypothesis (H0):

• Kulattha Gutika is not as effective as atorvastatin in the management of Dyslipidemia.

Alternate hypothesis (H1):

• Kulattha Gutika is as effective as Atorvastatin in the management of Dyslipidemia.

3. AIM AND OBJECTIVES

Aim: Comparative evaluation of Efficacy of Kulattha Gutika and Atorvastatin in the management of Dyslipidemia (Medoroga).

Objective:

1. To assess the efficacy of Kulattha Gutika on Total cholesterol, Triglyceride, HDL, LDL, VLDL & BMI.
2. To assess the efficacy of Atorvastatin on Total cholesterol, Triglyceride, HDL, LDL, VLDL & BMI.
3. To compare the efficacy of Kulattha Gutika and Atorvastatin on Total cholesterol, Triglyceride, HDL, LDL, VLDL & BMI.
4. To study the incidence of dyslipidemia as per prakruti.

4. METHODOLOGY

Type of trial - The trial is a parallel-group, randomized, single-blind, standard-controlled trial. It will include a 45 days treatment period, and a 15th, 30th, 45th day week follow-up period.

Allocation ratio – Total 60 patients will be selected for the study which will then be equally divided into two groups. Group A is experimental group whereas Group B is standard control.

Drug collection / authentication- The raw material will be procured from reliable source and will be authenticated from Department of Dravyaguna of Mahatma Gandhi Ayurved College, Hospital & Research Centre, Salod (H), Wardha.

Formulations:

Kulattha Gutika:

Table 1.

| Sr. No. | Ingredient | Botanical Name | Part Used | Quantity |
|---------|------------|----------------|-----------|----------|
| 1.      | Kulatthi   | Dolichos biflorus Linn. | Grains   | 1 Part   |

Preparation of Material (Kulattha Gutika):- The kulattha Gutika, will be prepare as per the standard operating procedures, mentioned in Sharangdhar Samhita, Madhyam Khand [17].
Properties of drugs [18] –

| Sr. No | Drug            | Rasa  | Guna       | Virya | Vipak             | Karma                           |
|-------|-----------------|-------|------------|-------|-------------------|---------------------------------|
| 1.    | KulatthaGutika  | Kashaya | Laghu, Ruksha, Ushan, Katu | Kaphavata Samaka Medohara |

**Study setting:** Selection of patients will be done from OPD and IPD of Department of Kayachikitsa, Mahatma Gandhi Ayurved College, Hospital & Research Centre, Salod (H), Wardha. Also patients will be selected from various specialized peripheral camps.

**Diagnostic criteria:** Diagnostic Criteria [19]
[ATP-III National cholesterol education program (NCEP) criteria]:
- Serum Total Cholesterol $\geq$ 200 mg/dl & or
- Serum Triglycerides = 150-499 mg/dl & or
- Serum HDL (HIGH DENSITY LIPID) $< 40$ mg/dl & or
- Serum LDL Cholesterol (LOW DENSITY LIPID) = 130-189 mg/dl

**Assessment criteria:** The patients will be assessed by objective parameters like lipid profile (Total cholesterol, Triglycerides, Low density lipoproteins, High density lipoproteins and Very low density lipoproteins), fasting blood sugar level and body mass index.

Prakruti will be assessed as per software application AYUVYA to study the incidence of dyslipidemia as per prakruti.

**Eligibility criteria:** Selection of patients in between the age group of 30–60 yrs of both gender and irrespective of the SharirikPrakruti will be considered. Patients with fulfilling the diagnostic criteria of Dyslipidemiaare included in the study. Patients with Pre-diagnosed cases of major illness like cardiovascular disorder, diabetes mellitus and renal disorders, Patients taking the medication like glucocorticoids and also pregnant and lactating women will be excluded.

**Randomization**- An independent statistician will create a block randomization sequence. Qualified individuals will be randomly assigned to either the experimental group or the conventional controlled group in a 1:1 ratio, with randomization stratified by site. A remote and web-based randomization system will be used by the researchers to assess the treatment allocation for each eligible participant. Total 60 patients will be selected for the study which will then be divided into two groups. Group A is experimental group where as Group B is standard controlled.

**Blinding**- Treatment allocations will be kept a secret from participants, the researcher will apply for a randomised assignment for each qualified patient by Random Sampling Computerized table method and will enrol him in study or control group. The blinding will not be broken during the trial and will be kept strictly confidential.

**Interventions:**

- **Group A** (Experimental) - Kulatthigutika 500 mg 2 tab. thrice a day before meal with warm water for 45 days.
- **Group B** (Standard Control) – Tab. Atorvastatin 10 mg once a day at bed time with warm water for 45 days.

**Screening investigations (base line):** Lipid profile, fasting blood sugar level.

**Investigation during treatment:** Not applicable.

**Investigation (end line):** Lipid profile, fasting blood sugar level.

**Criteria for discontinuing or modifying allocated interventions:** From the study if any untoward incidence, features of drug sensitivity or any other disease or problem arises, Subject will be withdrawn and free treatment will be offered to the subject till the difficulty subsides. We will measure quantity of Gutika for the consumption of appropriate dose for assessment and to check drug adherence during treatment the subject will be followed up.

**Follow up:** Patients will be followed up on 15th day, 30th day and 45th day during the period of treatment. Patient will be advised to take normal
Routine activity and routine diet and no any specific precautions for food intake will be advised.

**Primary Outcomes:** The primary outcome of the trial is to check the efficacy of interventional drug (Kulattha Gutika) on serum levels of Total cholesterol, Triglyceride, HDL, LDL, VLDL & BMI.

**Secondary Outcomes:** The secondary outcome of the trial is to study the incidence of dyslipidemia as per prakruti.

**Relief and relapse incidents:** Relapse is defined as a rise in lipid levels, blood sugar levels, or body mass index in patients with dyslipidemia (Medoroga) who had responded to treatment. When a patient's symptoms disappear, it signifies the treatment has been successful. The time until relief, time until first relapse, and total relapse times are the relief and relapse incident outcomes. The time between patients obtaining therapy and experiencing therapeutic success is referred to as the time until relief. The time to first relapse refers to the period of time between a patient's treatment success and the reintroduction of elevated cholesterol, sugar levels, or BMI. The sum of relapse times during both the treatment and follow-up periods is the total relapse time.

**Long-term effectiveness:** Long-term effectiveness responders are those who provide adequate relief on a weekly basis for at least 45 days throughout the follow-up period.

**Statistical analysis:** A statistically significant level of type I error is 5% (two-sided). Data of prakruti analysis be analysed with the help of Wilcoxon test. Paired as well as Unpaired t test will be used to analyse the data having objective criteria. The McNamara's test will be used to analyse the data with subjective criteria.

**Total follow up:** Patient will be followed up thrice during the trial, First on 15th day after initiating the treatment, second on 30th day after initiating the treatment, and third on 45th day i.e. after completion of the treatment.

**Follow up time:** The assessment of the patients will be done before and after completion of treatment.

**Enrolment and interventions time schedule:** Drugs will be given from 0 to 45 days with follow up on day 15th, day 30th and day 45th to check adherence of drug.

**Recruitment:** By computerized random chart sampling method 60 patient will be recruited (30 in each group).

**Implementation:** Principle investigator will enroll and allocate the patient.

**Methods:** Data collection, analysis and management.

**Data collection method:**

**Objectives:** Serum levels of Total cholesterol, LDL, HDL, VLDL, triglycerides, and BMI (Body Mass Index).

**Prakriti Assessment:** Prakriti will be assessed as per software application AYUVYA to study the incidence of dyslipidemia as per prakruti.

**Plan to promote participants retention and complete follow up:** We will stay in touch with the patient by taking contact number and timely advice them proper medication practices and follow up and the data regarding follow up will be stored in the documentation with valid reasons.

**Data management:** The data will be collected from patients by assessor by doing investigations and assessment after taking written consent form from the patient. Prakriti will be assessed with the help of software application AYUVYA will be collected using structured questionnaire filled during interview of the patient. Data will be entered in master sheet and analysed by using appropriate statistical technique and data coding will be done by principal investigator.

**Safety assessment:** On a consent form, details about adverse events will be noted, and on case sheet other details of patients will be noted. If there are any major adverse events, they must be reported to the principal investigator and the ethics committee within 24 hours, and any necessary therapy will be given as quickly as possible. All major adverse occurrences will be investigated and tracked until they are remedied.

**Dissemination policy:** The data will be disseminated by paper presentation and publication.

5. RESULT

Expected outcome result in control group with intervention Kulattha Gutikas per oral is
By assessing the Medohar effect of Kulatha Gutika, we will study the changes in Lipid Profile, BMI (Body Mass Index) of the subjects [31-38]. Since, the disorder involves Kaphadosha we will assess the prakriti of subjects so that a conclusion can be made that which subjects are more prone to dyslipidemia.

7. CONCLUSION

Kulatthi Gutika may prove more efficacious in improving serum lipid levels in Dyslipidemia (Medoroga) as compared to tablet Atorvastatin with minimum side effects.

CONSENT

The written consent will be taken before starting the study from the patient. During the study the confidentiality of each patient will be properly maintained.

ETHICS APPROVAL

Ethical Approval will be taken from research ethics committee for the trial Ref. No. MGACHRC / IEC / July – 2021/ 339.

NOTE

The study highlights the efficacy of “Ayurveda” which is an ancient tradition, used in some parts of India. This ancient concept should be carefully evaluated in the light of modern medical science and can be utilized partially if found suitable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Kasper D, et al. Harrison’s manual of internal medicine 18th edition chapter 356.
2. Munjal YP. API textbook of medicine. 9th ed. New Delhi: Jaypee Brothers Medical Publisher. 2012;1235.
3. Nandkarni M, et al. Randomized placebo controlled trial of Mustadighanavati in hyperlipidemia. AYU. 2010;31(3):287-93.
4. Sadhana Misar Wajpeyi. Analysis of etiological factors of Dyslipidemia -A case control study. International Journal of Ayurvedic Medicine. Jan Mar., 2020;11(1):92-97.
5. Shukla V, Charak Samhita, Volume-1, Charak Vimansthan, Chapter 5, Verse no 15, Varanasi: Chaukhamba Sanskrit Pratishthan; 2004.

6. Murthy KRS, Ashtanga Hridayam Vol 2 Nidansthanch 12 verse 1 Chaukhamba Krishnadas academy Varanasi reprint; 2006.

7. Yadavji T. Charakasamhita. Sutra Sthana. 20/17. Chaukhamba Orientalia Publisher: Varanasi. 2009;115-738.

8. Yadavji T. Charakasamhita. Sutra Sthana. 20/17. Chaukhamba Orientalia Publisher: Varanasi. 2009;115-738.

9. Hiware S, Parwe S. Role of Nitya Virechana in Medoroga--A case study. IAMJ. 2018;2:1085-9.

10. Sharma S. Ashtanga Sangastra, Varanasi, chaukhamba press, reprint 2008;151,965. Bulusu S Bhavaprakash Ed 2012. Vol I,chapter5 chaukhamba:5/60-62. Bulusu S Bhavaprakash Ed 2012. Vol 2 chapter 10 chaukhamba: Varanasi. 10/1-8.

11. Bulusu S Bhavaprakash Ed 2012. Vol 2 chapter 10 chaukhamba: Varanasi. 10/1-8.

12. Bulusu S Bhavaprakash Ed 2012. Vol 2 chapter 10 chaukhamba: Varanasi. 10/1-8.

13. Shipra Singh, Alok Kumar Srivastava. Clinical study to evaluate the efficacy of Vamana karma In the management of dyslipidemia.

14. Pooja BA, Santosh Kumar Bhatted, Meera K. Bhojani. A clinical study effect of lekhana basti in the management of dyslipidemia. Available:https://www.webmd.com/vitamins-and-supplements/guggul-uses-risks

15. Sharma PV. Dravyagunavijnana chaukhamba chapter1 page no.56 Guggul.

16. Srivastav S, Sharangdharasamhita. Ed reprint 2017. Madhyankanda, chaukhambha orientalia, Varanasi 117 p.

17. Sastry JLN. Dravyagunavijnana chaukhamba: Varanasi. 736-737.

18. NCEPATP3 guidelines. Available:http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf Accessed 15th Jan, 2016.

19. Mozaffarian D, Benjamim EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isassi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB. Heart Disease and Stroke Statistics-2016 Update: A report from the American Heart Association. Circulation. 2016 Jan 26. [PubMed PMID: 26673558]

20. Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS, Familial hypercholesterolaemia. Nature reviews. Disease Primers. 2017 Dec 7; [PubMed PMID: 29219151]

21. Shukla V, Charak Samhita, Volume-1, Charak Vimansthan, Chapter 5, Verse no 15, Varanasi: Chaukhamba Sanskrit Pratishthan; 2004. Agnivesh Charak Samhita, Vimanasthna 5/15-16, page713 By Kashinath Shastri & Gorakhnath Chaturvedi.

22. Bhonsle A, Parwe S, Nisargandha M. A comparative study to evaluate the efficacy of Lekhana Basti and modified Vachadi Gana Basti in combination with Navaka Guggulu in Sthaulya (Obesity)-A study protocol. Journal of Pharmaceutical Research International. 2021 Jun 2:154-61.

23. Harrison S Principal of Internal Medicine: 421: Disorders of Lipoprotein Metabolism Daniel J. Rader; Helen H. Hobbs. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Review. Semin Liver Dis. 2009;29:412–422.

24. Kottai Muthu A, Sethupathy S, Manavalan R, Karar PK. Hypolipidemic effect of methanolic extract of Dolichos biflorus Linn. in high fat diet fed rats.

25. Rasheed, Aamil, Sourya Acharya, Samarth Shukla, Sunil Kumar, Roopesh Yarappa, Yash Gupte, and Vidyashree Hulkoti. High-sensitivity C-reactive protein in metabolic healthy obesity (MHO). Journal of Evolution of Medical and Dental Sciences-JEMDS. February 17, 2020;9(7): 443–47. Available:https://doi.org/10.14260/jemds/2020/100

26. Acharya, Sourya, Samarth Shukla. Metabolic healthy obesity-A paradoxical fallacy? Journal of Clinical And Diagnostic Research. October 2018;12(10):CE7–10. Available:https://doi.org/10.7860/JCDR/2018/36809.12165.

27. Parwe S, Mohan M, Bhagwat P, Nisargandha M. Effect of Rodhradi Gana...
Udavartana in the Management of Sthaulya (Overweight) with special reference to obesity. International Journal of Life Science and Pharma Research. 2021 May;11(3):L30–7.

31. Bhonsle A, Parwe S, Nisargandha M. A comparative study to evaluate the efficacy of Lekhana Basti and modified Vachadi Gana Basti in combination with Navaka Guggulu in Sthaulya (Obesity) -A study protocol. Journal of Pharmaceutical Research International. 2021;33(30A):154–61.

32. Kakade, Tejas Laxman, Sadhana Misar Wajpeyi. Study in the effect of Yavavati in the management of Dyslipidemia. International Journal of Ayurvedic Medicine. June 2020;11(2): 265–70.

33. Wajpeyi, Sadhana Misar. Analysis of etiological factors of Dyslipidemia -A case control study. International Journal of Ayurvedic Medicine. March 2020;11(1):92–97.

34. Nagrale AV, Glynn P, Joshi A, Ramteke G. The efficacy of an integrated neuromuscular inhibition technique on upper trapezius trigger points in subjects with non-specific neck pain: A randomized controlled trial. Journal of Manual & Manipulative Therapy. 2010 Mar 1;18(1):37-43.

35. Khatib N, Gaidhane S, Gaidhane AM, Khatib M, Simkhada P, Gode D, Zahiruddin QS. Ghrelin: Ghrelin as a regulatory Peptide in growth hormone secretion. Journal of Clinical and Diagnostic Research: JCDR. 2014 Aug;8(8):MC13.

36. Agrawal A, Cincu R, Goel A. Current concepts and controversies in the management of non-functioning giant pituitary macroadenomas. Clinical Neurology and Neurosurgery. 2007 Oct 1;109(8):645-50.

37. Chole RH, Gondivkar SM, Gadbail AR, Balsaraf S, Chaudhary S, Dhole SV, Ghonmode S, Balwani S, Mankar M, Tiwari M, Parikh RV. Review of drug treatment of oral submucous fibrosis. Oral Oncology. 2012 May 1;48(5):393-8.

38. Korde SD, Basak A, Chaudhary M, Goyal M, Vagga A. Enhanced nitrosative and oxidative stress with decreased total antioxidant capacity in patients with oral precancer and oral squamous cell carcinoma. Oncology. 2011;80(5-6):382-9.